Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While Semaglutide is approved for type 2 diabetes and chronic weight management, significantly lowering HbA1c and body weight by modulating incretin pathways232480, Thymosin Beta-4 promotes wound healing, angiogenesis, and tissue regeneration in preclinical models via effects on cytoskeleton dynamics, cell migration, and anti-apoptotic pathways25579.
While Semaglutide works as a modified GLP-1(7–37) analog with three key changes—Ala8→Aib, Lys26 acylated with a C18 fatty diacid, and Lys34→Arg—resulting in a long-acting GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite23647480, Thymosin Beta-4 is an endogenous 43-amino-acid actin-sequestering peptide that maintains a pool of G-actin monomers and regulates actin polymerization, thereby influencing cell migration, proliferation, and differentiation25579.
Semaglutide
GCG
Thymosin Beta-4
TMSB4X
Semaglutide and Thymosin Beta-4 are noticeably different, with limited direct overlap in their usual biological context. Both are often discussed in Cardiovascular health contexts, while Semaglutide is more of a metabolic peptide and Hormone peptide and Thymosin Beta-4 is better described as a signal peptide and Cytokine peptide. Their biological logic is quite different: Semaglutide is a receptor agonist and a hormone analog, whereas Thymosin Beta-4 is a signaling modulator and a protein interaction inhibitor. Semaglutide has a more synthetic analog origin, while Thymosin Beta-4 is closer to natural endogenous background and their development context also differs, with Semaglutide approved while Thymosin Beta-4 is in Clinical phase 2. Semaglutide takes the form of a peptide conjugate, whereas Thymosin Beta-4 is closer to a linear peptide, Semaglutide carries lipidation features, while Thymosin Beta-4 instead reflects acetylation changes; while their sequence patterns also diverge, with Semaglutide showing alpha-helical domain features and Thymosin Beta-4 showing protein-mimetic sequence features.